Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

CO-DIAGNOSTICS, INC.

(CODX)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
12/01/2021 12/02/2021 12/03/2021 12/06/2021 12/07/2021 Date
9.17(c) 8.43(c) 8.35(c) 8.33(c) 8.56(c) Last
610 078 699 682 505 812 321 776 377 283 Volume
-4.88% -8.07% -0.95% -0.24% +2.76% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 98,4 M - -
Net income 2021 32,8 M - -
Net Debt 2021 - - -
P/E ratio 2021 7,81x
Yield 2021 -
Sales 2022 84,1 M - -
Net income 2022 16,3 M - -
Net Debt 2022 - - -
P/E ratio 2022 15,9x
Yield 2022 -
Capitalization 247 M 247 M -
Capi. / Sales 2021 2,51x
Capi. / Sales 2022 2,94x
Nbr of Employees 39
Free-Float 93,7%
More Financials
Company
Co-Diagnostics, Inc. is a molecular diagnostics company. The Company is engaged in developing, manufacturing and marketing diagnostics technology. Its reagents are used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules, such as deoxyribonucleic acid and ribonucleic acid. It also sells diagnostic equipment from other manufacturers as self-contained lab systems (MDx device). 
More about the company
Ratings of Co-Diagnostics, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
D+
More Ratings
All news about CO-DIAGNOSTICS, INC.
12/07Creator of COVID-19 and Global Molecular Testing Products Co-Diagnostics, Inc. Launches..
PR
12/07Co-Diagnostics JV Gets Nod from Indian Regulators for Multiplex Test
MT
12/07Co-Diagnostics JV CoSara Receives Clearance from Indian Regulators for ABC Multiplex Te..
PR
11/29Co-Diagnostics Says Its COVID-19 Tests Not Affected by Omicron Variant
MT
11/29Co-Diagnostics, Inc. Reports that Suite of COVID-19 Diagnostics Not Affected by Heavily..
PR
11/15Co-Diagnostics, Inc. to Host Booth at MEDICA 2021 Trade Fair in Düsseldorf, Germany
PR
11/12AFTER HOURS WATCH LIST SCORECARD : Mram, codx, afib
MT
11/12Co-Diagnostics Reports Continued Strength in Third Quarter 2021 Financial Results - For..
PU
11/12CO-DIAGNOSTICS, INC. Management's Discussion and Analysis of Financial Condition and R..
AQ
11/12CO-DIAGNOSTICS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8..
AQ
11/11MT NEWSWIRES AFTER HOURS WATCH LIST : Mram, codx, afib
MT
11/11Co-Diagnostics Q3 Results, Full-Year Guidance Top Estimates; Shares Up 16% After Hours
MT
11/11Earnings Flash (CODX) CO-DIAGNOSTICS Posts Q3 Revenue $30.1M, vs. Street Est of $24.3M
MT
11/11Co-Diagnostics Reports Continued Strength in Third Quarter 2021 Financial Results
PR
11/11Co-Diagnostics, Inc. Provides Earnings Guidance for the Full Year of 2021
CI
More news
News in other languages on CO-DIAGNOSTICS, INC.
12/07Co-Diagnostics JV obtient le feu vert des régulateurs indiens pour le test multiplexe
11/29Co-Diagnostics affirme que ses tests COVID-19 ne sont pas affectés par la variante Omic..
11/11Les résultats du troisième trimestre et les prévisions pour l'ensemble de l'année de Co..
11/11Earnings Flash (CODX) CO-DIAGNOSTICS affiche un chiffre d'affaires de 30,1 millions de ..
11/11Co-Diagnostics, Inc. fournit des prévisions de résultats pour l'année 2021.
More news
Analyst Recommendations on CO-DIAGNOSTICS, INC.
More recommendations
Chart CO-DIAGNOSTICS, INC.
Duration : Period :
Co-Diagnostics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CO-DIAGNOSTICS, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Last Close Price 8,56 $
Average target price 22,00 $
Spread / Average Target 157%
EPS Revisions
Managers and Directors
Dwight Howard Egan Chairman, President & Chief Executive Officer
Brian L. Brown Chief Financial Officer & Secretary
Jesse Montgomery Chief Scientific Officer
Richard S. Serbin Independent Director
Eugene Durenard Independent Director
Sector and Competitors
1st jan.Capi. (M$)
CO-DIAGNOSTICS, INC.-7.96%241
SARTORIUS AG42.61%39 650
BIOTAGE AB (PUBL)88.49%1 794
REVENIO GROUP OYJ6.26%1 601
VAREX IMAGING CORPORATION69.96%1 131
CELLAVISION AB (PUBL)4.82%827